Abstract
Hematopoietic stem cell transplantation (HSCT) represents the only cure for patients with thalassemia. At present, HSCT in younger patients from an HLA- matched sibling donor offers 80% to 87% probability of cure according to risk classes. However, results of HSCT in adult patients continue to be inferior due to advanced phase of disease. Highresolution tissue typing techniques have enabled transplant centres to offer allogeneic HSCT from unrelated donors to patients with thalassemia who could not benefit from matched sibling donor transplantation with results comparable to those obtained using sibling donors. Advances in transplantation biology have made it possible to perform haploidentical HSCT in patients with thalassemia who lack a related or unrelated matched donor. Although, limited number of patients, results of unrelated cord blood transplantation for thalassemia are encouraging. Patients with graft failure could now benefit from second transplantation using the same donor with a high disease-free survival rate. Most ex- thalassemics continue to have disease and treatment-related complications acquired before transplantation which require adequate treatment following BMT.
Keywords: Thalassemia, bone marrow transplantation, unrelated donor, haploidentical donor, unrelated cord blood transplantation, ex-thalassemics, thalassemias, hematopoiesis, Stem Cell Transplantation, Umiblical Cord Blood
Current Stem Cell Research & Therapy
Title: Hematopoietic Stem Cell Transplantation for Thalassemia
Volume: 6 Issue: 2
Author(s): Javid Gaziev and Guido Lucarelli
Affiliation:
Keywords: Thalassemia, bone marrow transplantation, unrelated donor, haploidentical donor, unrelated cord blood transplantation, ex-thalassemics, thalassemias, hematopoiesis, Stem Cell Transplantation, Umiblical Cord Blood
Abstract: Hematopoietic stem cell transplantation (HSCT) represents the only cure for patients with thalassemia. At present, HSCT in younger patients from an HLA- matched sibling donor offers 80% to 87% probability of cure according to risk classes. However, results of HSCT in adult patients continue to be inferior due to advanced phase of disease. Highresolution tissue typing techniques have enabled transplant centres to offer allogeneic HSCT from unrelated donors to patients with thalassemia who could not benefit from matched sibling donor transplantation with results comparable to those obtained using sibling donors. Advances in transplantation biology have made it possible to perform haploidentical HSCT in patients with thalassemia who lack a related or unrelated matched donor. Although, limited number of patients, results of unrelated cord blood transplantation for thalassemia are encouraging. Patients with graft failure could now benefit from second transplantation using the same donor with a high disease-free survival rate. Most ex- thalassemics continue to have disease and treatment-related complications acquired before transplantation which require adequate treatment following BMT.
Export Options
About this article
Cite this article as:
Gaziev Javid and Lucarelli Guido, Hematopoietic Stem Cell Transplantation for Thalassemia, Current Stem Cell Research & Therapy 2011; 6 (2) . https://dx.doi.org/10.2174/157488811795495413
DOI https://dx.doi.org/10.2174/157488811795495413 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Significant Role of MUC1 in Development of Resistance to Currently Existing Anti-cancer Therapeutic Agents
Current Cancer Drug Targets Exogenous Expression of WNT7A in Leukemia-Derived Cell Lines Induces Resistance to Chemotherapeutic Agents
Anti-Cancer Agents in Medicinal Chemistry Heat Shock Protein (HSP) Drug Discovery and Development: Targeting Heat Shock Proteins in Disease
Current Topics in Medicinal Chemistry The Therapeutical Potential of a Novel Pterocarpanquinone LQB-118 to Target Inhibitor of Apoptosis Proteins in Acute Myeloid Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry Developing Target Therapy Against Oncogenic Tyrosine Kinase in Myeloid Maliganacies
Current Pharmaceutical Biotechnology Antisense Oligonucleotide Drug Design
Current Pharmaceutical Design Single Autosomal Trisomy in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Current Genomics BIBR 1532 Increases Arsenic Trioxide-mediated Apoptosis in Acute Promyelocytic Leukemia Cells: Therapeutic Potential for APL
Anti-Cancer Agents in Medicinal Chemistry Is there any Role for Splenectomy in Adulthood Onset Chronic Immun e Thrombocytopenia in the Era of TPO Receptors Agonists? A Critic al Overview
Cardiovascular & Hematological Disorders-Drug Targets Interferon Treatment in Patients with Hypereosinophilia
Current Drug Targets Recent Patent-Based Perspective on Diagnostic and Therapeutic Interventions in Malignant Mesothelioma: Is Drug Repositioning Knocking on the Door?
Recent Patents on Anti-Cancer Drug Discovery Clofarabine as a Novel Nucleoside Analogue Approved to Treat Patients with Haematological Malignancies: Mechanism of Action and Clinical Activity
Mini-Reviews in Medicinal Chemistry Lymphadenopathy as a Prodrome for Systemic Lupus Erythematous
Current Rheumatology Reviews Stem Cell Transplantation in Pediatric Leukemia and Myelodysplasia: State of the Art and Current Challenges
Current Stem Cell Research & Therapy Pancreatic Cancer and Personalized Medicine: Can Genomics Facilitate Early Diagnosis or Improve Therapeutic Outcomes?
Current Pharmacogenomics and Personalized Medicine Abelson Tyrosine-Protein Kinase 1 as Principal Target for Drug Discovery Against Leukemias. Role of the Current Computer-Aided Drug Design Methodologies
Current Topics in Medicinal Chemistry Structure Based Lead Optimization Approach in Discovery of Selective DPP4 Inhibitors
Mini-Reviews in Medicinal Chemistry Stem Cell Technologies Based on Hemangioblast Technology Focusing on Human Blood Cells
Recent Patents on Drug Delivery & Formulation Targeting Apoptosis Resistance in Rhabdomyosarcoma
Current Cancer Drug Targets A Review on Noscapine, and its Impact on Heme Metabolism
Current Drug Metabolism